Sarquavitae acquired by Domusvi
Context
DomusVi has successfully acquired its Spanish competitor SARquavitae, previously held by a consortium of investment funds including Palamon Capital Partners and G Square Capital. This transformative build-up operation allows the group to become the number one player in the Spanish elderly care market. The strategic rationale centers on geographic diversification, as the target’s strong footprint in Catalonia and Madrid perfectly complements the acquirer’s existing position in Galicia. The integration adds 88 facilities and 11,000 beds to the group’s portfolio, bringing total pro forma revenues to approximately €1.2 billion. This acquisition marks a significant milestone in the group’s international expansion strategy, following the previous year’s integration of another Spanish operator, thereby solidifying its leadership position in Southern Europe.
Sarquavitae, which reported an EBITDA margin of [members only] in 2016, is valued in this transaction at an EV/EBITDA multiple of 10x–18x.
-> Deep-dive in Healthcare & Pharma market trends
Target
SARquavitae is a leading Spanish provider of elderly care services, operating an extensive network of 88 facilities with a total capacity of 11,000 beds. The entity maintains a particularly strong strategic presence in key regions including Catalonia and Madrid, complementing its historical operations. Its business model focuses on residential care and specialized medical services for the dependent elderly population. The company provides high-quality clinical and hospitality services, positioning itself as a primary competitor in the Iberian long-term care market. By integrating advanced healthcare management protocols, the group ensures a stable value proposition for both private residents and public regional healthcare systems. The organization has demonstrated consistent growth and operational stability, making it a pivotal asset for consolidation in the European healthcare infrastructure landscape.
Ent. Value
€300–700M
Equity Value
[members only]
Multiples
EV / Revenue
1x–3x
EV / EBITDA
10x–18x
EV / EBIT
[members only]
Historical Financials (EUR)
Other operations with Domusvi
Similar deals in Health Providers
| Date | Acquirer | Target | Country | Sector |
|---|---|---|---|---|
| 01/2017 | MARS | VCA | UNITED STATES | Vet Clinics |
| 01/2017 | PARTNERS GROUP / PSP INVESTMENTS | CERBA HEALTHCARE | FRANCE | Labs (Biology) |
| 05/2016 | VCA | COMPANION ANIMAL PRACTICES | UNITED STATES | Vet Clinics |
| 03/2016 | F2I SGR / CIR - COMPAGNIE INDUSTRIALI RIUNITE | KOS GROUP | ITALY | Nursing Homes |
| 02/2016 | OMERS | FOREFRONT DERMATOLOGY | UNITED STATES | Outpatient Care |
| 08/2015 | CINVEN | SYNLAB | GERMANY | Labs (Biology) |
| 07/2015 | ANTIN INFRASTRUCTURE | AMEDES | GERMANY | Labs (Biology) |
| 05/2015 | CINVEN | LABCO | FRANCE | Labs (Biology) |
| 04/2015 | SUMMIT PARTNERS / VAM INVESTMENTS | DENTALPRO | ITALY | Dental Centers |
| 01/2015 | CERBA HEALTHCARE | NOVESCIA | FRANCE | Labs (Biology) |
REFERENCES
Valuation range: EV €300–700M
Revenue range: €250–500M
EBITDA range: €25–50M
EV/Revenue range: 1x - 3x
EV/EBITDA range: 10x - 18x
Note: This page provides detailed data on a private equity M&A transaction. Detailed and exact financial metrics for the acquisition of Sarquavitae by Domusvi are reserved for mynth community members. Register for free to unlock full data.
Authors: This transaction was contributed by a verified mynth contributor and cross-checked against available transaction documents and official company communications.
FAQ
What transaction does this page cover?
How was the acquisition of Sarquavitae by Domusvi valued, and what multiples were paid?
What were Sarquavitae’s revenue and EBITDA at the time of the deal?
What sources support the information on this transaction?
What is mynth?